OKYO Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has authorized a single-patient expanded access (compassionate use) Investigational New Drug $(IND)$ application for the use of urcosimod (0.05%) in a patient with neuropathic corneal pain. The application was submitted by Pedram Hamrah, MD, at the University of South Florida. Urcosimod is being provided under the FDA-authorized expanded access program to a patient with severe neuropathic corneal pain, a condition for which there are currently no FDA-approved treatments. OKYO Pharma also noted that urcosimod was granted the first IND to treat patients with neuropathic corneal pain and was awarded fast track designation by the FDA. The company plans to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod for neuropathic corneal pain this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9631282-en) on January 23, 2026, and is solely responsible for the information contained therein.